INOVIQ Limited (EGQ0)

Profile

https://www.inoviq.com

INOVIQ Limited is a biotechnology company specializing in the development and commercialization of advanced diagnostic and exosome-based products, primarily aimed at improving early detection, monitoring, and treatment outcomes in oncology. Its innovative platforms encompass proprietary technologies such as EXO-NET® for exosome isolation, SubB2M™, NETs, BARD1, and hTERT, each supporting a robust pipeline of diagnostic tools and therapeutic candidates. INOVIQ’s solutions address significant unmet needs across cancer care, with products ranging from commercial research tools facilitating biomarker discovery, to clinical-stage diagnostics for ovarian and breast cancers, and emerging therapeutics for solid tumors. The company collaborates with global partners, notably distributing its exosome technologies through Promega Corporation, reflecting its international reach and growing revenue base. As a leader in exosome technology, INOVIQ plays a pivotal role in accelerating the adoption of precision diagnostics and novel therapies, contributing to advancements in global healthcare and the biotechnology sector.